Q-omics provides the consensus-scored NOP2 profile across patient tissues and cancer cell-line models. NOP2 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NOP2 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, NOP2 protein abundance shows 32,476 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight ACC, COAD, and LUAD as cancer lineages where NOP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NOP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NOP2 survival associations across molecular data types. NOP2 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (10) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NOP2 RNA expression–survival associations across cancer types. High NOP2 expression shows unfavorable associations in ACC, KIRC, KIRP, MESO, UVM and LIHC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NOP2 RNA expression.
This table summarizes NOP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NOP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NOP2 shows higher tumor expression in COAD, HNSC, KIRC, KIRP, BLCA and STAD. The COAD box plot shows higher NOP2 RNA expression in tumor versus normal tissue (log2 FC = +1.767, t-test p < 0.001).
This table shows molecular features associated with NOP2 in patient tissues and cancer cell lines. In patient samples, NOP2 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, NOP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
